Collins Cooper C. Acquires TherapeuticsMD Inc. (TXMD) Shares

TherapeuticsMD Inc. (NASDAQ:TXMD) finished Wednesday with an addition of $0.03 to close at $0.75, an upside of 3.45 percent. An average of 2,528,840 shares of common stock have been traded in the last five days. There was a gain of $0.0505 in the past week. The last 20 days have seen an average of 4,474,655 shares traded, while the 50-day average volume stands at 5,459,654.

TXMD stock has increased by 2.78% in the last month. The company shares reached their 1-month lowest point of $0.6700 on 09/21/21. With the stock rallying to its 52-week high on 02/09/21, shares of the company touched a low of $0.67 and a high of $2.75 in 52 weeks. In spite of this, the price is down -72.82% from the 52-week high.

A Backdoor Way To Profit From Today’s Crypto Bull Market

In any crypto bull market, there's a lot of money to be made.

But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?

This strategy is simply and ridiculously easy.

Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.


Insider Transactions

63 days have passed since TherapeuticsMD Inc. (TXMD) last reported insider trading activity. DArecca James, who is Chief Financial Officer, most recently acquired $93,337 shares at $0.87 per share on Aug 12. In this transaction, the insider spent $81,203. CAO and VP Finance, Donegan Michael C, disposed of 4,842 shares at a price of $1.04 on May 11. The insider now owns more than $5,036 worth of shares. Prior to that, General Counsel Walker Marlan D went on to Sale 21,592 shares at $1.04 each on May 11. An amount of $22,456 was transacted.

Valuation Metrics

TherapeuticsMD Inc. (TXMD) has a trailing price-to-earnings (P/E) ratio of 23.00 for the broader industry and 32.30 for the sector. The stock’s beta is 1.83. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.83.

The quick ratio of TherapeuticsMD Inc. for the three months ended June 29 was 2.00, and the current ratio was 2.10, indicating that the company is able to meet its debt obligations. On the profitability front, the trailing 12-month gross margin is 79.10% against a 5-year average of 81.7%. TherapeuticsMD Inc.’s EBITDA margin for the year ending June 29 is -231.33%. Its gross profit as reported stood at $48.9 million compared to revenue of $64.87 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, TherapeuticsMD Inc.’s return on assets was -77.50%, compared to -73.5% over the last five years.

Earnings Surprise

The analyst consensus anticipated TherapeuticsMD Inc.’s latest quarter earnings to come in at -$0.11 per share, but it turned out to be -$0.11, a 0.00% surprise. For the quarter, EBITDA amounted to -$35.41 million. Shareholders own equity worth $423.82 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at TherapeuticsMD Inc. (TXMD) price momentum. RSI 9-day as of the close on 13 October was 57.25%, suggesting the stock is Neutral, with historical volatility in this time frame at 53.37%.

As of today, TXMD’s price is $0.7116 +7.25% or $0.0505 from its 5-day moving average. TXMD is currently trading +3.32% higher than its 20-day SMA and -39.24% lower than its 100-day SMA. However, the stock’s current price level is -23.73% below the SMA50 and -38.74% below the SMA200.

The stochastic %K and %D were 37.74% and 26.52%, respectively, and the average true range (ATR) was 0.0358. With the 14-day stochastic at 67.95% and the average true range at 0.0379, the RSI (14) stands at 51.13%. The stock has reached 0.0048 on the 9-day MACD Oscillator while the 14-day reading was at -0.0035.

Analyst Ratings

Jefferies downgraded TherapeuticsMD Inc. (NASDAQ: TXMD) to a an Underperform rating in its most recent analyst report. Previously, the stock was rated as a a Hold.The consensus rating for TherapeuticsMD Inc. (TXMD) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell TXMD, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.

What is TXMD’s price target for the next 12 months?

Analysts predict a range of price targets between $4.00 and $5.00, with a median target of $5.00. Taking a look at these predictions, the average price target given by analysts for TherapeuticsMD Inc. (TXMD) stock is $4.75.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam